Rob as part of the Life Sciences group. He advises U.S. and European life sciences companies on a variety of transactions. In addition to day-to-day representation and strategic advice to his clients, he regularly handles IPOs and public offerings, mergers and acquisitions, joint ventures and other strategic collaborations.